Meanwhile, Chinese companies are rapidly advancing through fast following, innovation and licensing, with key developments including Innovents mazdutide, Innogens supaglutide, Hengruis oral candidate HRS-7535, United Laboratories licensing of its first-in-class triple-G (GLP-1, gastric inhibitory polypeptide (GIP) and glucagon) a gonist to Novo Nordisk and Ascletis positive Phase 1 results for its oral + injection candidate, ASC30
This gap in evidence means healthcare providers cannot definitively say the drugs are safe or unsafe during breastfeedingonly that the data is insufficient to recommend routine use
Zagroenia, skutki uboczne stosowania bez wskazania Leki GLP-1 na otyo i ryzyko raka Niektrzy pacjenci z otyoci stosuj agonistw GLP-1, eby schudn, niemniej moe to nie by jedyny korzystny efekt uboczny stosowania tej grupy lekw
This story was produced by GoodRx and reviewed and distributed by Stacker .